Aliskiren/ACE Inhibitors; ARBs Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
How this interaction occurs is not known.
What might happen:
Taking these medicines together may increase your risk of stroke, kidney problems, excessively low blood pressure, or low potassium levels in your blood.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together and if you have diabetes and/or kidney problems. Your doctor may want to check your blood pressure, perform some blood tests, or change your medicine. Let your doctor know if you feel faint, dizzy, confused, or have any symptoms of a stroke.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Anonymous. Novartis announces termination of ALTITUDE study with Rasilez/Tekturna in high-risk patients with diabetes and renal impairment. available at: https://www.fiercepharma.com/pharma/novartis-announces-termination-of-alti tude-study-rasilez%C2%AE-tekturna%C2%AE-high-risk-patients December, 20, 2011.
- 2.USFood and Drug Administration. FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekturna). available at: http://www.fda.gov/Drugs/DrugSafety/ucm300889.htm April 20, 2012.
- 3.Health Canada. Rasilez (aliskiren): Health Canada reviewing safety of blood-pressure drug. available at: http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/1357 2a-eng.php December 22, 2011.
- 4.Leclerc JM. Dear Canadian Healthcare Professional letter: Subject: Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ) or aliskiren/hydrochlorothiazide (RASILEZ HCT). Novartis January 18, 2012.
- 5.Zestril (lisinopril) US prescribing information. AstraZeneca Pharmaceuticals LP July 21, 2017.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.